Gamida Cell Says Actively Pursuing Strategic Alternatives
Benzinga · 01/29 11:01

While pursuing strategic alternatives, the company continues to put its focus and resources behind the commercialization of Omisirge® (omidubicel-onlv), the first and only FDA-approved nicotinamide modified cell therapy donor source for allogeneic stem cell transplant.